CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, announced that the presentation made by Geert Kersten, Chief Executive Officer of CEL-SCI, at the 8th annual LD Micro Main Event on Thursday, December 3rd is available on CEL-SCI's website at http://www.cel-sci.com/investor_relations.html. The replay of the presentation will be available for 90 days.

About CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care (SOC) as compared to subjects treated with the current SOC only, is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase 1 trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase 1 trial in conjunction with the U.S. Naval Medical Center, San Diego, under a CRADA and University of California, San Francisco (UCSF).

CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

CEL-SCI CorporationGavin de Windt, 703-506-9460

Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cel Sci Charts.
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cel Sci Charts.